Loading...
NPI 1922055094 · Manchester, NH · Mobile Radiology Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Merrimack Valley Pet PC is a mobile radiology clinic/center provider located in Manchester, New Hampshire. This profile covers 5 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Merrimack Valley Pet PC |
| Address | 185 Queen City Ave |
| City | Manchester |
| State | NH |
| ZIP | 03101 |
| Taxonomy | Mobile Radiology Clinic/Center |
| NPI Enumerated | May 27, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $941.9K |
| Medicaid | $14.9K |
MERRIMACK VALLEY PET PC bills as a Mobile Radiology Clinic/Center and its Medicare and Medicaid activity is overwhelmingly centered on PET imaging and PET radiopharmaceuticals. The provider's top Medicare codes include A9595, 78815, and A9552, and these CPT/HCPCS descriptions (diagnostic PET radiotracers and combined PET/CT imaging) point to a focused, imaging-first operation rather than a multispecialty outpatient practice.
Medicare revenue is highly concentrated in a very small set of services: the top 3 Medicare codes by revenue account for 95.5% of this provider's total Medicare revenue. Specifically, A9595 generated $426.3K (45.3% of total Medicare revenue), 78815 generated $369.9K (39.3%), and A9552 generated $102.8K (10.9%), together driving nearly all Medicare dollars recorded ($941.9K total Medicare revenue).
Medicaid billing is similarly concentrated: the precomputed top-3 Medicaid codes account for 100.0% of the provider's Medicaid revenue, with 78815 contributing $10K (67.0% of Medicaid revenue) and A9552 contributing $4.9K (33.0% of Medicaid revenue) out of $14.9K total Medicaid revenue. This indicates Medicaid activity is limited to the same PET/PET–CT service lines the provider bills to Medicare.
The provider is effectively Medicare-dominant in scale: lifetime Medicare revenue is $941.9K versus lifetime Medicaid revenue of $14.9K, indicating a payer mix heavily weighted toward Medicare and a comparatively minimal Medicaid footprint. For analysts this suggests operational and reimbursement risk is primarily tied to Medicare policy and PET reimbursement rather than state Medicaid dynamics.
Competitive standing on Medicare shows relatively high national percentile placement for the top PET codes but is described by the dataset as typical for volume. A9595 ranks #41 of 528 (92th percentile) while 78815 ranks #568 of 6566 (91th percentile) and A9552 ranks #228 of 2411 (91th percentile); the accompanying plain-English characterization labels these volumes as "typical, unremarkable volume for this code," implying above-average placement in peer lists but not an outsized or dominant national franchise.
Medicaid competitive signals are limited and unstable because the in-state peer sets are very small. For Medicaid, 78815 ranks #4 of 4 in-state (0th percentile) and A9552 ranks #2 of 3 in-state (50th percentile); combined with the low absolute Medicaid revenue ($14.9K), this suggests the provider is not a major Medicaid imaging supplier in-state and rank interpretation is fragile due to tiny peer counts.
The code mix and volumes imply a mobile PET provider model focused on oncology/metabolic imaging, given the heavy use of PET/CT (78815) and PET radiotracers (A9595 and A9552). Operational implications include reliance on radiopharmaceutical procurement and logistics as key cost and capacity drivers, and potential sensitivity to reimbursement changes or supply constraints for those specific tracers and PET/CT imaging.
The provider has a long tenure on file — NPI enumerated 2006-05-27 (~20 years ago) — which indicates an established presence in its market. Coupled with the concentrated revenue profile and modest absolute scale outside Medicare, this suggests a stable, niche mobile PET operator with limited diversification across payers or imaging modalities.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | 890 | $480 | $426.3K |
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 310 | $1,200 | $369.9K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 250 | $410 | $102.8K |
| 78816 | The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The… | 20 | $1,200 | $27.6K |
| 78608 | In this diagnostic procedure, the provider performs PET, positron emission tomography, a type of nuclear imaging test. It tells how the brain is functioning with information on metabolism, such as… | 20 | $1,010 | $15.2K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 10 | $710 | $10K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 20 | $310 | $4.9K |
How this provider's Medicaid billing volume and revenue compare to other New Hampshire providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Hampshire median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 4 | 10 | 50 | $110 | $36.3K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 2 | 10 | 20 | $30 | $4.1K |
Other providers in the same ZIP code as Merrimack Valley Pet PC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.